AIMD AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
AIMD Current Performance
-1.08%
Ainos inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to AIMD
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
APYX | Apyx medical corp | 2 | 2 | 2 | 1 | 1 | |
STRR | Star equity holdings inc | 3 | 3 | 2 | 1 | 1 | |
POAI | Predictive oncology inc | - | 3 | 3 | 1 | 1 | |
MOVE | Movano inc | 2 | 3 | 4 | - | 1 | |
PODD | Insulet corp | 4 | 5 | 2 | 2 | 1 |
- APYX Apyx medical corpValue 2Trend 2Swing Trading 2Whale Interest 1Dividend 1See more
AIMD Profile
Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.